Zacks: Analysts Anticipate Fate Therapeutics Inc (NASDAQ:FATE) Will Post Earnings of -$0.38 Per Share

Wall Street analysts expect Fate Therapeutics Inc (NASDAQ:FATE) to post earnings per share of ($0.38) for the current quarter, according to Zacks. Seven analysts have issued estimates for Fate Therapeutics’ earnings, with estimates ranging from ($0.45) to ($0.29). Fate Therapeutics reported earnings per share of ($0.30) during the same quarter last year, which would indicate a negative year over year growth rate of 26.7%. The business is scheduled to issue its next earnings report on Tuesday, May 5th.

According to Zacks, analysts expect that Fate Therapeutics will report full year earnings of ($1.63) per share for the current year, with EPS estimates ranging from ($2.07) to ($1.36). For the next fiscal year, analysts expect that the company will post earnings of ($1.79) per share, with EPS estimates ranging from ($2.29) to ($1.48). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Fate Therapeutics.

Fate Therapeutics (NASDAQ:FATE) last released its quarterly earnings data on Monday, March 2nd. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.02. Fate Therapeutics had a negative net margin of 919.00% and a negative return on equity of 49.94%. The company had revenue of $2.80 million during the quarter, compared to analyst estimates of $1.70 million. During the same period in the prior year, the firm earned ($0.25) earnings per share. The firm’s revenue for the quarter was up 68.7% compared to the same quarter last year.

FATE has been the subject of a number of research reports. BidaskClub lowered shares of Fate Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, March 18th. BTIG Research upped their price objective on shares of Fate Therapeutics from to and gave the stock a “buy” rating in a research note on Tuesday, March 3rd. Zacks Investment Research lowered shares of Fate Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, February 21st. BMO Capital Markets increased their price target on shares of Fate Therapeutics from to in a research report on Tuesday, March 3rd. Finally, Barclays began coverage on shares of Fate Therapeutics in a research report on Wednesday, March 4th. They set an “overweight” rating and a $40.00 price target for the company. Four analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $33.94.

In other news, insider Bahram Valamehr sold 5,700 shares of the company’s stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $20.69, for a total transaction of $117,933.00. Following the transaction, the insider now owns 91,758 shares in the company, valued at $1,898,473.02. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO J Scott Wolchko sold 25,000 shares of the company’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $25.45, for a total transaction of $636,250.00. Following the transaction, the chief executive officer now owns 444,969 shares in the company, valued at approximately $11,324,461.05. The disclosure for this sale can be found here. Corporate insiders own 23.19% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Lindbrook Capital LLC acquired a new position in shares of Fate Therapeutics during the fourth quarter valued at about $39,000. Meeder Asset Management Inc. increased its holdings in shares of Fate Therapeutics by 46.1% during the fourth quarter. Meeder Asset Management Inc. now owns 2,029 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 640 shares in the last quarter. TFG Advisers LLC acquired a new position in shares of Fate Therapeutics during the fourth quarter valued at about $42,000. Quantbot Technologies LP increased its holdings in shares of Fate Therapeutics by 1,133.3% during the fourth quarter. Quantbot Technologies LP now owns 3,700 shares of the biopharmaceutical company’s stock valued at $72,000 after acquiring an additional 3,400 shares in the last quarter. Finally, Great West Life Assurance Co. Can acquired a new position in shares of Fate Therapeutics during the fourth quarter valued at about $83,000. Hedge funds and other institutional investors own 95.07% of the company’s stock.

NASDAQ:FATE traded down $0.09 during mid-day trading on Friday, reaching $23.31. The company’s stock had a trading volume of 834,442 shares, compared to its average volume of 1,120,458. Fate Therapeutics has a 1 year low of $12.59 and a 1 year high of $32.39. The stock has a fifty day moving average of $26.65 and a 200-day moving average of $20.14. The firm has a market capitalization of $1.81 billion, a PE ratio of -16.30 and a beta of 1.71. The company has a quick ratio of 8.17, a current ratio of 8.17 and a debt-to-equity ratio of 0.10.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system.

Further Reading: Roth IRA

Get a free copy of the Zacks research report on Fate Therapeutics (FATE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.